1-9 of 9
Michael Amatangelo, PhD
Close
Sort by
Journal Articles

FOXM1 Is Associated with Development of Therapeutic Resistance in Multiple Myeloma

Michael Amatangelo, PhD, Maria Ortiz, Paola Neri, MD, Fadi Towfic, PhD, Chad Bjorklund, Jian Kang, Erica Sternberg, Nizar J. Bahlis, MD, Matthew Trotter, PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1261.
https://doi.org/10.1182/blood.V130.Suppl_1.1261.1261
Published: 2017
Journal Articles

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Lynn Quek, FRCPath, DPhil, MBBS, Muriel David, Alison Kennedy, MSc, Marlen Metzner, MSc, Michael Amatangelo, PhD, Alan H. Shih, MD PhD, Bilyana Stoilova, PhD, Dimitris Karamitros, PhD, Cyril Quivoron, Mael Heiblig, MD, Christophe Willekens, MD, Veronique Saada, Andrew Peniket, Olivier Bernard, Sam Agresta, MD, Katharine Yen, Eytan M. Stein, MD, Stephane De Botton, Anjan Thakurta, PhD, Ross L. Levine, MD, Virginie Penard-Lacronique, PhD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 724.
https://doi.org/10.1182/blood.V130.Suppl_1.724.724
Published: 2017
Journal Articles

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Xiaozhong Qian, Meletios A. Dimopoulos, Michael Amatangelo, PhD, Chad Bjorklund, Katja C. Weisel, Enrique M. Ocio, MDPhD, Xin Yu, Teresa Peluso, Lars Sternas, Mohamed Zaki, Philippe Moreau, MDPhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3109.
https://doi.org/10.1182/blood.V130.Suppl_1.3109.3109
Published: 2017
Journal Articles

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients

Andrew P Dervan, Michael Mason, PhD, Fadi Towfic, PhD, Michael Amatangelo, PhD, Daniel Auclair, PhD, Douglas Bassett, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Samuel Danziger, PhD, Erin Flynt, PhD, Hartmut Goldschmidt, MD, Justin Guinney, PhD, Dirk Hose, MD, Konstantimos Mavrommatis, PhD, Gareth J. Morgan, MD PhD, Nikhil Munshi, MD, Alexander Ratushny, PhD, Dan Rozelle, PhD, Mehmet Kemal Samur, PhD, Frank Schmitz, MD PhD, Kenneth H Shain, MD PhD, Matthew Trotter, PhD, Brian A Walker, PhD, Brian S. White, PhD, Thomas Yu, BS, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 265.
https://doi.org/10.1182/blood.V130.Suppl_1.265.265
Published: 2017
Journal Articles

CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2016) 128 (22): 1591.
https://doi.org/10.1182/blood.V128.22.1591.1591
Published: 2016
Journal Articles

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2016) 128 (22): 1592.
https://doi.org/10.1182/blood.V128.22.1592.1592
Published: 2016
Journal Articles

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Eytan M. Stein, MD, Amir T. Fathi, MD, Courtney D DiNardo, MD, Daniel A Pollyea, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Gail J. Roboz, MD, Robert Collins, Mikkael A. Sekeres, MD, Richard M. Stone, MD, Eyal C Attar, Alessandra Tosolini, BS, Qiang Xu, PhD, Michael Amatangelo, PhD, Ira Gupta, MD, Robert D. Knight, MD, Stéphane De Botton, MD PhD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 343.
https://doi.org/10.1182/blood.V128.22.343.343
Published: 2016
Journal Articles

The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

Brian A Walker, PhD, Mehmet K. Samur, PhD, Konstantinos Mavrommatis, Cody Ashby, PhD, Christopher P Wardell, PhD, Maria Ortiz, PhD, Fadi Towfic, Caleb K. Stein, MS, Michael A Bauer, PhD, Michael Amatangelo, PhD, Giovanni Parmigiani, PhD, Zhinuan Yu, PhD, Matthew Trotter, Herve Avet-Loiseau, MD PhD, Graham H Jackson, MD PhD, Kenneth C. Anderson, Anjan Thakurta, PhD, Nikhil C. Munshi, MD, Gareth J Morgan, MD PhD
Journal: Blood
Blood (2016) 128 (22): 196.
https://doi.org/10.1182/blood.V128.22.196.196
Published: 2016
Journal Articles

IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance

Courtney G. Havens, PhD, Chad Bjorklund, PhD, Jian Kang, BS, Maria Ortiz, PhD, Celia Fontanillo, PhD, Michael Amatangelo, PhD, Ling Lu, BS, Paola E. Neri, MD PhD, Antonia Lopez-Girona, PhD, Nizar J. Bahlis, MD, Anjan Thakurta, PhD, Mathew Trotter, MD, Anita K. Gandhi, PhD, Anke Klippel, PhD, Rajesh Chopra, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3432.
https://doi.org/10.1182/blood.V124.21.3432.3432
Published: 2014